<SEC-DOCUMENT>0001140361-23-009092.txt : 20230228
<SEC-HEADER>0001140361-23-009092.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228111930
ACCESSION NUMBER:		0001140361-23-009092
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228
GROUP MEMBERS:		ALEXANDER J. DENNER, PH.D.
GROUP MEMBERS:		LOUIS STERLING III

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-52399
		FILM NUMBER:		23680734

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>brhc10049017_sc13da.htm
<DESCRIPTION>SC 13D/A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
  <div><br>
    <div>
      <div style="text-align: center;"><font style="font-size: 14pt; font-weight: bold;">UNITED STATES</font><font style="font-size: 14pt;"><br>
        </font><font style="font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</font><br>
        <font style="font-size: 12pt;">Washington, D.C. 20549</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">SCHEDULE 13D</div>
      <div><br>
      </div>
      <div style="text-align: center;">Under the Securities Exchange Act of 1934</div>
      <div style="text-align: center;">(Amendment No. 12)*<br>
        <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb18d8e9d6b0f488b9f23c25df3f90c17">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 24pt;">
              <div style="text-align: center;">Amarin Corporation plc</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(Name of Issuer)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center;">Ordinary Shares, par value 50 pence per share</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(Title of Class of Securities)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center;">023111206</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(CUSIP Number)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center;">Mark DiPaolo</div>
              <div style="text-align: center;">Senior Partner, General Counsel</div>
              <div style="text-align: center;">Sarissa Capital Management LP</div>
              <div style="text-align: center;">660 Steamboat Road</div>
              <div style="text-align: center;">Greenwich, CT 06830</div>
              <div style="text-align: center;">203-302-2330</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(Name, Address and Telephone Number of Person<br>
                Authorized to Receive Notices and Communications)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center;">February 28, 2023</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: center;">(Date of Event which Requires Filing of this Statement)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify;">If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g),
        check the following box. </div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Note:</font>&#160; Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies
        are to be sent.</div>
      <div>&#160;</div>
      <div>*The remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures
        provided in a prior cover page.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The information required on the remainder of this cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that
        section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
    </div>
    <div><br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z1802fda4eb2842a5bf987562a3f8c2bf">

          <tr>
            <td style="width: 33.33%;">
              <div style="text-align: left;">CUSIP No. 023111206</div>
            </td>
            <td style="width: 34%; text-align: center;">
              <div>SCHEDULE 13D</div>
            </td>
            <td style="width: 33.33%;">
              <div style="text-align: right;">Page 2 of 4 Pages</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">This Amendment No. 12 to Schedule 13D (&#8220;Amendment No. 12&#8221;) relates to American Depositary Shares (&#8220;ADS(s)&#8221;), each ADS representing one ordinary share, par value 50 pence per share (the &#8220;Ordinary Shares&#8221;), issued by
      Amarin Corporation plc, a company incorporated under the laws of England and Wales (the &#8220;Issuer&#8221;), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on January 24, 2022 (the &#8220;Initial
      Schedule 13D&#8221;), as amended by Amendment No. 1 to Schedule 13D filed on June 3, 2022, Amendment No. 2 to Schedule 13D filed on June 16, 2022, Amendment No. 3 to Schedule 13D filed on October 11, 2022, Amendment No. 4 to Schedule 13D filed on January
      11, 2023, Amendment No. 5 to Schedule 13D filed on January 19, 2023, Amendment No. 6 to Schedule 13D filed on February 8, 2023, Amendment No. 7 to Schedule 13D filed on February 10, 2023, Amendment No. 8 to Schedule 13D filed on February 14, 2023,
      Amendment No. 9 to Schedule 13D filed on February 15, 2023, Amendment No. 10 to Schedule 13D filed on February 21, 2023 and Amendment No. 11 to Schedule 13D filed on February 27, 2023 (the Initial Schedule 13D as so amended, the &#8220;Schedule 13D&#8221;). All
      capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">This Amendment No. 12 is being filed to amend Item 4 and Item 7 as follows:</div>
    <div>&#160;</div>
    <div><font style="font-weight: bold;">Item 4.&#160; Purpose of Transaction. </font>Item 4 of the Schedule 13D is hereby amended to include the following:</div>
    <div>&#160;</div>
    <div style="text-align: justify;">On February 28, 2023, Sarissa Capital issued the press release attached as Exhibit 15 hereto.</div>
    <div>&#160;</div>
    <div style="text-align: justify;"><font style="font-weight: bold;">Item 7.&#160; Material to Be Filed as Exhibits. </font>Item 7 of the Schedule 13D is hereby amended to include the following:</div>
    <div>&#160;</div>
    <div>Exhibit 15 &#8211; Press Release, February 28, 2023</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 33.33%;">
                <div style="text-align: left;">CUSIP No. 023111206</div>
              </td>
              <td style="width: 34%; text-align: center;">
                <div>SCHEDULE 13D</div>
              </td>
              <td style="width: 33.33%;">
                <div style="text-align: right;">Page 3 of 4 Pages</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">SIGNATURE</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">
      <div style="text-indent: 36pt;">After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.</div>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z3a4f2641042c46cd832899d47cd33f6e" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div>Dated: February 28, 2023</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div>SARISSA CAPITAL MANAGEMENT LP</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid black;">
              <div>/s/ Mark DiPaolo</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>Name: Mark DiPaolo</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div>Title: Senior Partner, General Counsel</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; border-bottom: 2px solid black;" colspan="2">
              <div>/s/ Alexander J. Denner</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div>Alexander J. Denner</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; border-bottom: 2px solid black;" colspan="2">
              <div>/s/ Louis Sterling III</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div>Louis Sterling III</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 33.33%;">
                  <div style="text-align: left;">CUSIP No. 023111206</div>
                </td>
                <td style="width: 34%; text-align: center;">
                  <div>SCHEDULE 13D</div>
                </td>
                <td style="width: 33.33%;">
                  <div style="text-align: right;">Page 4 of 4 Pages</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">INDEX TO EXHIBITS</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="zb2850c25d0a34bf3a4dea1e91e564c56">

        <tr>
          <td style="width: 100.00%;">
            <div style="text-align: left;">
              <div><a href="brhc10049017_ex15.htm">Exhibit 15</a> &#8211; Press Release, February 28, 2023</div>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div><br>
    <br>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.15
<SEQUENCE>2
<FILENAME>brhc10049017_ex15.htm
<DESCRIPTION>EXHIBIT 15
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; font-weight: bold;">EXHIBIT 15</div>
    <div style="text-align: right;"> <br>
    </div>
  </div>
  <div style="text-align: center; font-weight: bold;">SARISSA CAPITAL WINS PROXY CONTEST AGAINST AMARIN BY HUGE LANDSLIDE</div>
  <div><br>
  </div>
  <div style="text-align: center; font-weight: bold;">Sarissa honored to have received 100 million more votes than Amarin board</div>
  <div><br>
  </div>
  <div style="text-align: justify;">Greenwich, CT, February 28, 2023 &#8211; Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):</div>
  <div><br>
  </div>
  <div>Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is that up to nearly 80% of
    shareholder votes were in support of Sarissa. As Amarin&#8217;s largest shareholder, we are grateful for the opportunity to remake Amarin for the benefit of all shareholders.</div>
  <div><br>
  </div>
  <div>Vascepa, the foundation on which Amarin is built, is a tremendous drug that is compelling for patients and payors &#8211; a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa&#8217;s
    rare and highly beneficial profile to unlock tremendous value for all shareholders.</div>
  <div><br>
  </div>
  <div style="font-weight: bold;"><u>LET&#8217;S GET TO WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL SHAREHOLDERS!</u></div>
  <div><br>
  </div>
  <div style="font-weight: bold;">Additional Information</div>
  <div><br>
  </div>
  <div>Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of
    Amarin Corporation plc (the &#8220;Company&#8221;) at the general meeting of the Company for the election of Sarissa Capital&#8217;s slate of highly-qualified nominees (the &#8220;General Meeting&#8221;). Shareholders are advised to read the definitive proxy statement and other
    relevant documents related to the General Meeting as they contain important information.</div>
  <div><br>
  </div>
  <div>The definitive proxy statement and other relevant documents are available at no charge on the SEC&#8217;s website at <u>www.sec.gov</u> and at <u>www.freeamarin.com</u>. The definitive proxy statement and other relevant documents are also available at
    no charge by directing a request to Sarissa Capital&#8217;s proxy solicitor, D.F. King &amp; Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).</div>
  <div><br>
  </div>
  <div>#FreeAmarin </div>
  <div> <br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z479d0dcb6d4045288b9422a6bbe873af">

      <tr>
        <td style="width: 72pt; vertical-align: top;">Contact:</td>
        <td style="width: auto; vertical-align: top;">
          <div>Dayna Packes<br>
            Sarissa Capital Management LP<br>
            info@sarissacap.com</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div><br>
  </div>
  <div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
